The prevalence of HCV in the U.S. is 0.93%, and 51.9% of patients with HCV reside in nine states.
In the late 2000s the CDC estimated that 3.5 million persons were living with hepatitis C virus (HCV) in the U.S. Since then, treatment with direct-acting antivirals and an increase in incidence secondary to the opioid crisis have changed the epidemiology of HCV, including state-to-state variations. Using several data sources and a multistep statistical approach, investigators updated data on HCV prevalence at the state level.
Based on U.S. National Health and Nutrition Examination Survey (NHANES) data, the estimated HCV prevalence was 0.8%. When populations absent from NHANES (institutionalized and homeless) were included, the adjusted HCV prevalence was 0.9%, corresponding to 2,266,700 persons with HCV infection in the period 2013–2016. HC…
Reviewing Author
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)